SNES SenesTech, Inc.
Agricultural Chemicals · Nasdaq · SEC CIK 1680378 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY20.9%
TTM net income YoY-31.2%
TTM EPS YoY41.2%
Revenue 3-yr CAGR32.5%
Net income 3-yr CAGR—
Margins
Gross margin69.5%
Operating margin-282.4%
Net margin-275.3%
FCF margin-239.3%
EBITDA margin-277.8%
Returns
ROE-96.0%
ROA-67.2%
ROIC (approx.)-263.0%
Asset turnover0.24x
Leverage & solvency
Liabilities / assets43.5%
Debt / equity0.00x
Current ratio4.51x
Interest coverage-413.32x
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-9.1%
Payout ratio—
Capex / revenue1.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.22M | $1.86M |
| Cost of revenue | $833,000 | $853,000 |
| Gross profit | $1.39M | $1.00M |
| R&D expense | $1.70M | $1.71M |
| SG&A expense | $6.20M | $5.54M |
| Operating income | -$6.50M | -$6.25M |
| Interest expense | $22,000 | $22,000 |
| Income tax | $0 | $0 |
| Net income | -$6.38M | -$6.18M |
| EBITDA | -$6.37M | -$6.09M |
| EPS (basic) | -1.95 | -8.86 |
| EPS (diluted) | -1.95 | -8.86 |
| Weighted avg. shares (diluted) | 3.28M | 697,974 |
| Balance sheet | ||
| Cash & equivalents | $7.58M | $1.31M |
| Short-term investments | $994,000 | $0 |
| Receivables | $201,000 | $335,000 |
| Inventory | $994,000 | $794,000 |
| Current assets | $10.06M | $2.81M |
| PP&E, net | $410,000 | $407,000 |
| Total assets | $12.84M | $3.28M |
| Current liabilities | $798,000 | $561,000 |
| Total liabilities | $3.27M | $767,000 |
| Shareholders' equity | $9.57M | $2.51M |
| Shares outstanding | 5.22M | 1.04M |
| Cash flow statement | ||
| Operating cash flow | -$5.75M | -$6.03M |
| Capital expenditure | $138,000 | $84,000 |
| Free cash flow | -$5.89M | -$6.12M |
| Investing cash flow | -$1.10M | -$56,000 |
| Financing cash flow | $13.12M | $2.00M |
| Depreciation & amortization | $135,000 | $156,000 |
| Stock-based compensation | $264,000 | $326,000 |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.